AbbeGen, a next-generation early-stage biopharmaceutical company founded by Nigerian-American venture capitalist and businessman Joshua Oduyemi, is pioneering a global movement in the fight against cancer and autoimmune diseases through its cutting-edge pipeline of CAR-T cell therapies, antibody-drug conjugates (ADCs), and small molecules. With a clear mission to expand access to life-saving therapies across both developed and underserved regions, AbbeGen is positioning itself at the forefront of therapeutic innovation.
The company is utilizing advanced technologies such as Chimeric Antigen Receptor T-cell (CAR-T) therapies, Antibody-Drug Conjugates (ADCs), and small molecules to target and treat various forms of cancer and autoimmune disorders. AbbeGen's innovative approach is based on developing targeted therapies that aim to improve the lives of patients suffering from complex diseases.
CAR-T cell therapies, which involve modifying a patient's own immune cells to fight cancer, have shown promise in clinical trials for hematologic cancers. ADCs combine the specificity of monoclonal antibodies with the potency of chemotherapy, delivering a targeted treatment that minimizes damage to healthy tissue. Small molecules are being developed to interfere with disease processes at a cellular level, offering a novel way to treat diseases once considered challenging to manage.
Joshua Oduyemi, who is also the General Partner and Group CEO of Sheatrust Capital, brings a wealth of experience in venture capital and the pharmaceutical industry. His vision for AbbeGen is clear: to revolutionize the treatment of cancer and autoimmune diseases through innovation, advanced science, and a commitment to accessibility in underserved regions.
During an interview with Vanguard journalist, Joshua Oduyemi emphasized the company's unique approach:
"We are not just developing medicines -- we're building bridges to health equity. From day one, the goal was to design a platform capable of treating aggressive cancers and complex autoimmune disorders while making these therapies accessible in places often excluded from innovation, particularly in parts of Africa," said Oduyemi.
Brian Warner, CEO of AbbeGen and a seasoned executive in global biotech development, also shared insights during the interview:
"What excites me about AbbeGen is its balance of scientific rigor and global compassion. Our drug development programs are guided by strong preclinical science and a regulatory mindset that allows us to move quickly -- not just in the U.S. and Europe, but also in emerging markets. Our partnerships in West Africa, for example, are helping us build capacity for future clinical trials on the continent."
Oduyemi added: "Cancer and autoimmune diseases are two of the leading causes of death globally. Our therapies, from CAR-T cells to ADCs and small molecules, offer a more precise and effective way of treating these diseases. With our pipeline of innovative treatments, we are not just treating symptoms but aiming to eradicate the underlying causes of these diseases."
Warner further explained: "Our focus on building strategic partnerships with healthcare providers and working with government is key. We are also working closely with local organizations to ensure that our treatments are affordable and accessible. By bringing cutting-edge therapies to market, we can change the way cancer and autoimmune diseases are treated globally."
AbbeGen's research and development efforts are not limited to the West. Oduyemi is particularly interested in expanding the company's reach to global markets and the African continent, where access to advanced treatments remains limited. By creating affordable, accessible therapies, AbbeGen aims to address critical healthcare gaps in regions with the highest burden of these diseases.
"The healthcare systems in the U.S., Europe, and Africa are vastly different, but the need for effective cancer and autoimmune treatments is universal," said Oduyemi. "We are focusing on creating scalable solutions that can be adapted to different markets. Our hope is that by providing innovative therapies, we can reduce the disease burden globally, especially in historically underserved regions."
AbbeGen plans to initiate Phase 1 clinical trials for its lead CAR-T therapy (ABG-101) in early 2026, with IND-enabling studies already underway. The company is also in active discussions with regulatory authorities in the U.S., EU, and select African nations to align trial design with global safety and efficacy standards.
AbbeGen is committed to transparency, patient-centric research, and forging strategic partnerships with research institutions and healthcare organizations to accelerate the development and distribution of its therapies. The company is actively involved in clinical trials, with an eye on approval in major markets across the globe. Their dedication to improving healthcare outcomes and their innovative approach to developing therapies has positioned AbbeGen as a promising player in the global pharmaceutical landscape.
Looking Ahead
Sign up for free AllAfrica Newsletters
Get the latest in African news delivered straight to your inbox
As AbbeGen continues to advance its research and development efforts, Oduyemi's commitment to creating life-changing therapies is clear. His background in both finance and healthcare provides a unique perspective on how to approach challenges in the pharmaceutical industry, and his vision is resonating with stakeholders across the globe. In the coming years, Oduyemi anticipates expanding AbbeGen's portfolio, with more therapies in development and a broader global presence.
When asked about the company's global impact, Oduyemi responded: "We believe in the power of targeted treatments, whether through CAR-T, ADCs, or small molecules. Our therapies are designed to be precise and efficient, reducing the burden of treatment while improving outcomes. In regions like Africa, where cancer and autoimmune diseases are rising, we aim to provide affordable and effective options to fight these diseases head-on."
Oduyemi's focus on innovation, accessibility, and global health equity has set AbbeGen apart as a company to watch in the pharmaceutical sector. As the company continues to grow, it holds the potential to reshape the future of cancer and autoimmune disease treatment on a global scale.
